nyse:dgx
|
4727
|
Apr 21st, 2024 12:00AM
|
Quest Diagnostics
|
278K
|
27726
|
Open
|
|
Apr 21st, 2024 03:51AM
|
Apr 21st, 2024 03:51AM
|
Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.
The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion.
Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories.
Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients.
Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions.
The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals.
More information is available at www.questdiagnostics.com.
Language Assistance / Non-Discrimination Notice
Asistencia de Idiomas / Aviso de no Discriminación
語言協助 / 不歧視通知
www.QuestDiagnostics.com/home/nondiscrimination
|
Open
|
Diagnostic testing information and services, Clinical testing, cancer diagnostics and anatomic pathology services, Gene-based and other esoteric testing, and Healthcare information technology solutions
|
Open
|
500 Plaza Drive
|
Secaucus
|
NJ
|
US
|
07094
|
|
Quest Diagnostics
|
Health Care
|
Health Care Equipment & Services
|
nyse:dgx
|
4727
|
Apr 20th, 2024 12:00AM
|
Quest Diagnostics
|
278K
|
27726
|
Open
|
|
Apr 20th, 2024 01:59AM
|
Apr 20th, 2024 06:13PM
|
Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.
The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion.
Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories.
Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients.
Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions.
The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals.
More information is available at www.questdiagnostics.com.
Language Assistance / Non-Discrimination Notice
Asistencia de Idiomas / Aviso de no Discriminación
語言協助 / 不歧視通知
www.QuestDiagnostics.com/home/nondiscrimination
|
Open
|
Diagnostic testing information and services, Clinical testing, cancer diagnostics and anatomic pathology services, Gene-based and other esoteric testing, and Healthcare information technology solutions
|
Open
|
500 Plaza Drive
|
Secaucus
|
NJ
|
US
|
07094
|
|
Quest Diagnostics
|
Health Care
|
Health Care Equipment & Services
|
nyse:dgx
|
4727
|
Apr 19th, 2024 12:00AM
|
Quest Diagnostics
|
278K
|
27715
|
Open
|
|
Apr 19th, 2024 05:14AM
|
Apr 19th, 2024 05:14AM
|
Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.
The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion.
Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories.
Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients.
Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions.
The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals.
More information is available at www.questdiagnostics.com.
Language Assistance / Non-Discrimination Notice
Asistencia de Idiomas / Aviso de no Discriminación
語言協助 / 不歧視通知
www.QuestDiagnostics.com/home/nondiscrimination
|
Open
|
Diagnostic testing information and services, Clinical testing, cancer diagnostics and anatomic pathology services, Gene-based and other esoteric testing, and Healthcare information technology solutions
|
Open
|
500 Plaza Drive
|
Secaucus
|
NJ
|
US
|
07094
|
|
Quest Diagnostics
|
Health Care
|
Health Care Equipment & Services
|
nyse:dgx
|
4727
|
Apr 18th, 2024 12:00AM
|
Quest Diagnostics
|
278K
|
27711
|
Open
|
|
Apr 18th, 2024 01:57AM
|
Apr 18th, 2024 07:33PM
|
Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.
The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion.
Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories.
Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients.
Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions.
The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals.
More information is available at www.questdiagnostics.com.
Language Assistance / Non-Discrimination Notice
Asistencia de Idiomas / Aviso de no Discriminación
語言協助 / 不歧視通知
www.QuestDiagnostics.com/home/nondiscrimination
|
Open
|
Diagnostic testing information and services, Clinical testing, cancer diagnostics and anatomic pathology services, Gene-based and other esoteric testing, and Healthcare information technology solutions
|
Open
|
500 Plaza Drive
|
Secaucus
|
NJ
|
US
|
07094
|
|
Quest Diagnostics
|
Health Care
|
Health Care Equipment & Services
|
nyse:dgx
|
4727
|
Apr 17th, 2024 12:00AM
|
Quest Diagnostics
|
278K
|
27711
|
Open
|
|
Apr 17th, 2024 05:03AM
|
Apr 17th, 2024 04:00PM
|
Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.
The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion.
Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories.
Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients.
Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions.
The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals.
More information is available at www.questdiagnostics.com.
Language Assistance / Non-Discrimination Notice
Asistencia de Idiomas / Aviso de no Discriminación
語言協助 / 不歧視通知
www.QuestDiagnostics.com/home/nondiscrimination
|
Open
|
Diagnostic testing information and services, Clinical testing, cancer diagnostics and anatomic pathology services, Gene-based and other esoteric testing, and Healthcare information technology solutions
|
Open
|
500 Plaza Drive
|
Secaucus
|
NJ
|
US
|
07094
|
|
Quest Diagnostics
|
Health Care
|
Health Care Equipment & Services
|
nyse:dgx
|
4727
|
Apr 16th, 2024 12:00AM
|
Quest Diagnostics
|
278K
|
27702
|
Open
|
|
Apr 16th, 2024 01:54AM
|
Apr 16th, 2024 12:17PM
|
Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.
The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion.
Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories.
Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients.
Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions.
The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals.
More information is available at www.questdiagnostics.com.
Language Assistance / Non-Discrimination Notice
Asistencia de Idiomas / Aviso de no Discriminación
語言協助 / 不歧視通知
www.QuestDiagnostics.com/home/nondiscrimination
|
Open
|
Diagnostic testing information and services, Clinical testing, cancer diagnostics and anatomic pathology services, Gene-based and other esoteric testing, and Healthcare information technology solutions
|
Open
|
500 Plaza Drive
|
Secaucus
|
NJ
|
US
|
07094
|
|
Quest Diagnostics
|
Health Care
|
Health Care Equipment & Services
|
nyse:dgx
|
4727
|
Apr 15th, 2024 12:00AM
|
Quest Diagnostics
|
278K
|
27702
|
Open
|
|
Apr 15th, 2024 05:32AM
|
Apr 15th, 2024 05:57PM
|
Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.
The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion.
Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories.
Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients.
Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions.
The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals.
More information is available at www.questdiagnostics.com.
Language Assistance / Non-Discrimination Notice
Asistencia de Idiomas / Aviso de no Discriminación
語言協助 / 不歧視通知
www.QuestDiagnostics.com/home/nondiscrimination
|
Open
|
Diagnostic testing information and services, Clinical testing, cancer diagnostics and anatomic pathology services, Gene-based and other esoteric testing, and Healthcare information technology solutions
|
Open
|
500 Plaza Drive
|
Secaucus
|
NJ
|
US
|
07094
|
|
Quest Diagnostics
|
Health Care
|
Health Care Equipment & Services
|
nyse:dgx
|
4727
|
Apr 14th, 2024 12:00AM
|
Quest Diagnostics
|
278K
|
27683
|
Open
|
|
Apr 14th, 2024 12:33AM
|
Apr 14th, 2024 12:15PM
|
Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.
The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion.
Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories.
Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients.
Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions.
The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals.
More information is available at www.questdiagnostics.com.
Language Assistance / Non-Discrimination Notice
Asistencia de Idiomas / Aviso de no Discriminación
語言協助 / 不歧視通知
www.QuestDiagnostics.com/home/nondiscrimination
|
Open
|
Diagnostic testing information and services, Clinical testing, cancer diagnostics and anatomic pathology services, Gene-based and other esoteric testing, and Healthcare information technology solutions
|
Open
|
500 Plaza Drive
|
Secaucus
|
NJ
|
US
|
07094
|
|
Quest Diagnostics
|
Health Care
|
Health Care Equipment & Services
|
nyse:dgx
|
4727
|
Apr 13th, 2024 12:00AM
|
Quest Diagnostics
|
277K
|
27674
|
Open
|
|
Apr 13th, 2024 12:18AM
|
Apr 13th, 2024 12:42PM
|
Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.
The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion.
Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories.
Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients.
Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions.
The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals.
More information is available at www.questdiagnostics.com.
Language Assistance / Non-Discrimination Notice
Asistencia de Idiomas / Aviso de no Discriminación
語言協助 / 不歧視通知
www.QuestDiagnostics.com/home/nondiscrimination
|
Open
|
Diagnostic testing information and services, Clinical testing, cancer diagnostics and anatomic pathology services, Gene-based and other esoteric testing, and Healthcare information technology solutions
|
Open
|
500 Plaza Drive
|
Secaucus
|
NJ
|
US
|
07094
|
|
Quest Diagnostics
|
Health Care
|
Health Care Equipment & Services
|
nyse:dgx
|
4727
|
Apr 12th, 2024 12:00AM
|
Quest Diagnostics
|
277K
|
27675
|
Open
|
|
Apr 12th, 2024 12:28AM
|
Apr 12th, 2024 09:39AM
|
Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.
The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion.
Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories.
Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients.
Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions.
The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals.
More information is available at www.questdiagnostics.com.
Language Assistance / Non-Discrimination Notice
Asistencia de Idiomas / Aviso de no Discriminación
語言協助 / 不歧視通知
www.QuestDiagnostics.com/home/nondiscrimination
|
Open
|
Diagnostic testing information and services, Clinical testing, cancer diagnostics and anatomic pathology services, Gene-based and other esoteric testing, and Healthcare information technology solutions
|
Open
|
500 Plaza Drive
|
Secaucus
|
NJ
|
US
|
07094
|
|
Quest Diagnostics
|
Health Care
|
Health Care Equipment & Services
|